Alagille Syndrome Market Research Report – Forecast to 2027

Alagille Syndrome Market Research Report: By Symptom (Liver Problems, Nutrition Problems, Heart Problems, Other), by Treatment (Medications, Kidney Surgery, Other), by Diagnosis (Blood Test, Urinalysis, X-ray Imaging, Other), by End-User– Global Forecast Till 2027

ID: MRFR/Pharma/4863-HCR | | Region: Global | 100 pages

Market Scenario

Global alagille syndrome market is expected to grow significantly over the forecast period. Alagille syndrome is a rare genetic condition that can affect the liver and other parts of the body. An individual having alagille syndrome has a fewer number of small bile ducts inside the liver. This causes the bile to build-up inside the liver, which in turn causes liver scarring and damage. Moreover, the signs and symptoms of this syndrome are generally noticed in infancy or early childhood.

The growing occurrence of alagille syndrome, increasing healthcare expenditure, and rising prevalence of genetic diseases are anticipated to drive the growth of the market. According to the US National Library of Medicine, the estimated prevalence of alagille syndrome is 1 in 70,000 newborns.

Despite the drivers, lack of awareness about the syndrome in the developing regions may hamper the growth of the market during the assessment period.

Segmentation

The global alagille syndrome market has been segmented into symptom, treatment, diagnosis, and end-user.

The market on the basis of symptom has been segmented into liver problems, nutrition problems, heart problems, distinctive facial features, neurologic problems, and others.

The market, by treatment, has been segmented into medication, biliary diversion procedures, vitamin supplements, liver transplantation, kidney surgery, heart surgery, and others. The medication segment has been further segmented into Ursodeoxycholic acid, cholestyramine, rifampin, naltrexone, and anti-histamine. The anti-histamine segment has been further segmented into hydroxyzine and others.

The market, by diagnosis, has been segmented into blood test, urinalysis, X-ray imaging, cardiology exam, slit-lamp exam, liver biopsy, genetic testing, prenatal DNA testing, and others.

On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The alagille syndrome market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European alagille syndrome market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The alagille syndrome market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The alagille syndrome market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergen Plc, Lannett, Albireo Pharma, Inc., AstraZeneca Plc, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc. are some of the key players in the global alagille syndrome market.


Regional Market Summary


Global Alagille Syndrome Market Share (%), by Region, 2017


Alagille Syndrome Market


Source: MRFR Analysis


Geographically, the Americas is anticipated to dominate the global alagille syndrome market owing to a well-developed healthcare sector, rising prevalence of rare genetic disease and growing healthcare expenditure. According to the Global Genes Project, rare and genetic diseases affect 1 in 10 people in the United States Additionally, increasing awareness among the people regarding the disease and well-developed technology is likely to contribute to the growth of the market.


Europe is expected to hold the second largest position in the global alagille syndrome market. The market growth in this region is attributed to the growing prevalence of several liver diseases, increasing prevalence of genetic disease, availability of funds for research, and increasing healthcare expenditure. According to the Public Health England, approximately 11,597 number of people died with an underlying cause of liver disease in England in 2014.  In addition, according to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rare diseases and increasing government funding for the healthcare sector.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Global Alagille Syndrome Market, by Symptom



  • Liver Problems

  • Nutrition Problems

  • Heart Problems

  • Distinctive Facial Features

  • Neurologic Problems

  • Others


Global Alagille Syndrome Market, by Treatment



  • Medications

  • Ursodeoxycholic Acid

  • Cholestyramine

  • Rifampin

  • Naltrexone

  • Anti-histamines

  • Hydroxyzine

  • Others

  • Biliary Diversion Supplements

  • Vitamin supplements

  • Liver Transplantation

  • Kidney Surgery

  • Heart Surgery

  • Others


Global Alagille Syndrome Market, by Diagnosis



  • Blood Test

  • Urinalysis

  • X-ray Imaging

  • Cardiology Exam

  • Slit-lamp Exam

  • Liver Biopsy

  • Genetic Testing

  • Prenatal DNA testing

  • Others


Global Alagille Syndrome Market, by End-User



  • Hospitals and Clinics

  • Diagnostic Centers

  • Others


Global Alagille Syndrome Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa



  • Middle East

  • Africa


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2019-2027:Substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Symptom, Treatment, Diagnosis, And End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergen Plc, Lannett, Albireo Pharma, Inc., AstraZeneca Plc, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc
  Key Market Opportunities   Increasing government funding for the healthcare sector
  Key Market Drivers

  • Increasing healthcare expenditure
  • Rising prevalence of genetic diseases



    • Frequently Asked Questions (FAQ) :

    Alagille market may suffer a setback due to a lack of awareness.

    Symptoms included in the alagille syndrome market are nutrition problems, liver problems, distinctive facial features, neurologic problems, heart problems, and others.

    The segments in alagille syndrome market report are biliary diversion procedures, medication, liver transplantation, vitamin supplements, heart surgery, kidney surgery, and others.

    The segments included in alagille syndrome market report are urinalysis, prenatal DNA testing, blood test, slit-lamp exam, X-ray imaging, cardiology exam, genetic testing, liver biopsy, and others.

    The end users involved in alagille syndrome market report are diagnostic centers, hospitals & clinics, and others.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Alagille Syndrome Market, by Symptom

    6.1 Introduction

    6.2 Liver Problems

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Nutrition Problems

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4 Heart Problems

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.5 Distinctive Facial Features

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.6 Neurologic Problems

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.7 Others

    Chapter 7. Global Alagille Syndrome Market, by Treatment

    7.1 Introduction

    7.2 Medication

    7.2.1 Ursodeoxycholic Acid

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.2 Cholestyramine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.3 Rifampin

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.4 Naltrexone

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.5 Anti-histamines

    7.2.5.1 Hydroxyzine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.5.2 Others

    7.3 Biliary Diversion Procedures

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.4 Vitamin Supplements

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.5 Liver Transplantation

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.6 Kidney Surgery

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.7 Heart Surgery

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.8 Others

    Chapter 8. Global Alagille Syndrome Market, by Diagnosis

    8.1 Introduction

    8.2 Blood Test

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.3 Urinalysis

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 X-ray Imaging

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.5 Cardiology Exam

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.6 Slit-Lamp Exam

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.7 Liver Biopsy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.8 Genetic Testing

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.9 Prenatal DNA Testing

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.10 Others

    Chapter 9. Global Alagille Syndrome Market, by End-User

    9.1 Introduction

    9.2 Hospital and Clinics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.3 Diagnostic Centers

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.4 Others

    Chapter 10. Global Alagille Syndrome Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12. Company Profiles

    12.1 Sanofi AG

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Teva Pharmaceutical Industries Ltd.

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Allergan Plc

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Lannett

    12.4.1 Company Overview

    12.4.2 Product Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Albireo Pharma, Inc.

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 AstraZeneca Plc

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Novartis AG

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Pfizer, Inc.

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Shire

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Bristol-Myers Squibb Company

    12.10.1 Overview

    12.10.2 Product Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 GlaxoSmithKline Plc

    12.11.1 Overview

    12.11.2 Product Overview

    12.11.3 Financials

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.12 Merck & Co., Inc.

    12.12.1 Overview

    12.12.2 Product Overview

    12.12.3 Financials

    12.12.4 Key Developments

    12.12.5 SWOT Analysis

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s Viewpoint

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Predictions for the Alagille Syndrome Industry

    Chapter 14. Appendix

    LIST OF TABLES

    Table 1 Global Alagille Syndrome Market Synopsis, 2020–2027

    Table 2 Global Alagille Syndrome Market Estimates and Forecast, 2020–2027 (USD Million)

    Table 3 Global Alagille Syndrome Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 5 Global Alagille Syndrome Market, by Treatment, 2020–2027(USD Million)

    Table 6 Global Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 7 Global Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    Table 8 North America: Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 9 North America: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 10 North America: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 11 North America: Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    Table 12 US: Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 13 US: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 14 US: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 15 US: Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    Table 16 Canada: Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 17 Canada: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 18 Canada: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 19 Canada: Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    Table 20 South America: Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 21 South America: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 22 South America: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 23 South America: Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    Table 24 Europe: Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 25 Europe: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 26 Europe: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 27 Europe: Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    Table 28 Western Europe: Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 29 Western Europe: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 30 Western Europe: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 31 Western Europe: Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    Table 32 Eastern Europe: Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 33 Eastern Europe: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 34 Eastern Europe: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 35 Eastern Europe: Alagille Syndrome Market, by End-User, 2020–2027(USD Million)

    Table 36 Asia-Pacific: Alagille Syndrome Market, by Symptom, 2020–2027 (USD Million)

    Table 37 Asia-Pacific: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 38 Asia-Pacific: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 39 Asia-Pacific: Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    Table 40 Middle East & Africa: Alagille Syndrome Market, by Symptom, 2020–2027

    (USD Million)

    Table 41 Middle East & Africa: Alagille Syndrome Market, by Treatment, 2020–2027 (USD Million)

    Table 42 Middle East & Africa: Alagille Syndrome Market, by Diagnosis, 2020–2027 (USD Million)

    Table 43 Middle East & Africa: Alagille Syndrome Market, by End-User, 2020–2027 (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Alagille Syndrome Market

    Figure 3 Segmentation Market Dynamics for Global Alagille Syndrome Market

    Figure 4 Global Alagille Syndrome Market Share, by Symptom, 2020

    Figure 5 Global Alagille Syndrome Market Share, by Treatment, 2020

    Figure 6 Global Alagille Syndrome Market Share, by Diagnosis, 2020

    Figure 7 Global Alagille Syndrome Market Share, by End-User, 2020

    Figure 8 Global Alagille Syndrome Market Share, by Region, 2020

    Figure 9 North America: Alagille Syndrome Market Share, by Country, 2020

    Figure 10 Europe: Alagille Syndrome Market Share, by Country, 2020

    Figure 11 Asia-Pacific: Alagille Syndrome Market Share, by Country, 2020

    Figure 12 Middle East & Africa: Alagille Syndrome Market Share, by Country, 2020

    Figure 13 Global Alagille Syndrome Market: Company Share Analysis, 2020 (%)

    Figure 14 Sanofi AG: Key Financials

    Figure 15 Sanofi AG: Segmental Revenue

    Figure 16 Sanofi AG: Geographical Revenue

    Figure 17 Teva Pharmaceutical Industries Ltd.: Key Financials

    Figure 18 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

    Figure 19 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

    Figure 20 Allergan Plc: Key Financials

    Figure 21 Allergan Plc: Segmental Revenue

    Figure 22 Allergan Plc: Geographical Revenue

    Figure 23 Lannett : Key Financials

    Figure 24 Lannett: Segmental Revenue

    Figure 25 Lannett: Geographical Revenue

    Figure 26 Albireo Pharma, Inc.: Key Financials

    Figure 27 Albireo Pharma, Inc.: Segmental Revenue

    Figure 28 Albireo Pharma, Inc. Geographical Revenue

    Figure 29 AstraZeneca Plc: Key Financials

    Figure 30 AstraZeneca Plc: Segmental Revenue

    Figure 31 AstraZeneca Plc: Geographical Revenue

    Figure 32 Novartis AG: Key Financials

    Figure 33 Novartis AG: Segmental Revenue

    Figure 34 Novartis AG: Geographical Revenue

    Figure 35 Pfizer, Inc.: Key Financials

    Figure 36 Pfizer, Inc.: Segmental Revenue

    Figure 37 Pfizer, Inc.: Geographical Revenue

    Figure 38 Shire: Key Financials

    Figure 39 Shire: Segmental Revenue

    Figure 40 Shire: Geographical Revenue

    Figure 41 Bristol-Myers Squibb Company: Key Financials

    Figure 42 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 43 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 44 GlaxoSmithKline Plc: Key Financials

    Figure 45 GlaxoSmithKline Plc: Segmental Revenue

    Figure 46 GlaxoSmithKline Plc: Geographical Revenue

    Figure 47 Merck & Co., Inc.: Key Financials

    Figure 48 Merck & Co., Inc: Segmental Revenue

    Figure 49 Merck & Co., Inc: Geographical Revenue